These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18564222)

  • 21. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
    Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
    Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation.
    Högenauer C; Langner C; Lipp RW; Höfler G; Krejs GJ; Hinterleitner TA
    Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):323-7. PubMed ID: 12610329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
    Kleinbaum EP; Lazar AJ; Tamborini E; Mcauliffe JC; Sylvestre PB; Sunnenberg TD; Strong L; Chen LL; Choi H; Benjamin RS; Zhang W; Trent JC
    Int J Cancer; 2008 Feb; 122(3):711-8. PubMed ID: 17943734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.
    Hasan S; Hassan M; Oke L; Dinh K; Onojobi G; Lombardo F; Dawkins F; Jack M
    J Natl Med Assoc; 2003 Dec; 95(12):1208-10. PubMed ID: 14717479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
    Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
    Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
    Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
    Kantarjian HM; Talpaz M
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of STI-571, a c-kit tyrosine kinase inhibitor, in mestastasic gastrointestinal tumor].
    Calvo E; Fernández FJ; Forteza J; Brugarolas A
    Med Clin (Barc); 2002 Sep; 119(10):396-7. PubMed ID: 12372175
    [No Abstract]   [Full Text] [Related]  

  • 35. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysregulation of tyrosine kinases and use of imatinib in small animal practice.
    Bonkobara M
    Vet J; 2015 Aug; 205(2):180-8. PubMed ID: 25592261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Tamborini E; Negri T; Miselli F; Lagonigro MS; Pricl S; Pilotti S
    J Natl Cancer Inst; 2006 Nov; 98(21):1583-4. PubMed ID: 17077361
    [No Abstract]   [Full Text] [Related]  

  • 40. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.